Saira Ramasastry - 01 Jun 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Sung Lee, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
01 Jun 2023
Net transactions value
-$89,845
Form type
4
Filing time
02 Jun 2023, 12:19:36 UTC
Previous filing
24 May 2023
Next filing
14 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Sale $89,845 -3,500 -25% $25.67 10,619 01 Jun 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.